Lamivudine Teva (Lamivudine)

Lamivudine is converted inside cells to its active triphosphate form, which mimics natural nucleosides. When reverse transcriptase incorporates lamivudine triphosphate into viral DNA, it causes chain termination, preventing the virus from completing its genetic material and thereby halting replication.

The specific dose of Lamivudine Teva is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and other individual factors. Healthcare professionals follow approved dosing guidelines and adjust as needed.

Safety data for lamivudine in pregnancy are limited, and the drug is classified as pregnancy category unknown. Clinicians must weigh potential benefits against possible risks, and breastfeeding decisions should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class and is often combined with other antiretrovirals for synergistic effect. Compared with newer agents, lamivudine has a well‑established safety profile, but resistance can develop if used as monotherapy, making combination regimens preferred.

Lamivudine tablets should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct sunlight. Do not store in humid environments such as bathrooms or near heat sources.

Lamivudine Teva is taken orally, usually with or without food, as directed by the prescriber. The tablet should be swallowed whole with water and not chewed or crushed unless specifically advised by a healthcare professional.

The most serious adverse events include lactic acidosis, severe hepatotoxicity, and rare hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be monitored for unexplained fatigue, abdominal pain, rapid breathing, or skin eruptions and seek immediate medical attention if they occur.

Lamivudine is contraindicated in patients with known hypersensitivity to lamivudine or any of its excipients. Caution is also advised for individuals with severe renal impairment, active liver disease, or those taking contraindicated medications such as didanosine.